Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06988605 · ClinicalTrials.gov registry record
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
A clinical trial of Atopic Dermatitis, sponsored by Galderma R&D.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 20
- Study locations
NCT06988605 is a study of Atopic Dermatitis that is actively recruiting participants, run by Galderma R&D. The registered enrollment target is 1,000 participants, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (66% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT06988605, a study of Atopic Dermatitis, is actively recruiting participants, sponsored by Galderma R&D.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Conditions Studied
Study Locations (20)
California
- Galderma Investigational Site - 7074 - Corona
- Galderma Investigational Site 8636 - Fountain Valley
- Galderma Investigational Site 8224 - Fremont
- Galderma Investigational Site 7099 - Los Angeles
- Galderma Investigational Site 8553 - Newport Beach
- Galderma Investigational Site 7064 - Santa Monica
- Galderma Investigational Site 7107 - Thousand Oaks
Florida
- Galderma Investigational Site 8597 - Boca Raton
- Galderma Investigational Site 7087 - Coral Gables
- Galderma Investigational Site 7063 - Cutler Bay
- Galderma Investigational Site 7134 - Hollywood
- Galderma Investigational Site 7101 - Jupiter
- Galderma Investigational Site 7078 - Miami
Arizona
- Galdrma Investigational Site - 7077 - Phoenix
- Galderma Investigational Site 7060 - Phoenix
- Galderma Investigational Site - 8535 - Phoenix
- Galderma Investigational Site - 7067 - Tucson
Alabama
- Galderma Investigational Site - 8893 - Birmingham
Colorado
- Galderma Investigational Site 7061 - Castle Rock
Connecticut
- Galderma Investigational Site 7059 - Fairfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-07-14 |
| Est. Completion | 2027-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06988605
The ClinicalTrials.gov registry entry for NCT06988605 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (66% higher). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 0 interventions.
NCT06988605 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06988605 about?
NCT06988605 is a clinical study titled "Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults". The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
What is the current status of trial NCT06988605?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-07-14. Estimated completion is 2027-11-30.
What conditions does trial NCT06988605 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
Who is sponsoring clinical trial NCT06988605?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06988605 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry for Systemic Eczema Treatments
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.